• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU 2.17% $21.22

NEUREN PHARMACEUTICALS LIMITED

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
NEU
NEU chart
25 26 27
20:39 1.5K 791K
20:39 Last post  WESTHOT Comments Created with Sketch.  1.5K  Views Created with Sketch.  791K 
NEU
Share Price
20:37 9.6K 4.3M
20:37 Last post  WESTHOT Comments Created with Sketch.  9.6K  Views Created with Sketch.  4.3M 
NEU
Neuren - where to from here ?
2
17:10 65 26K
TRENDING NEWS

Diversification and low trading fees: Is this the ‘secret sauce’ to saving your investment portfolio?

NEWS
28 Mar 2024
17:10 Last post  comora Comments Created with Sketch.  65  Views Created with Sketch.  26K 
NEU
Market Capitalisation is a Better Valuation Metric Than Share Price
2
16:32 100 61K
16:32 Last post  In4apenny Comments Created with Sketch.  100  Views Created with Sketch.  61K 
NEU
ROW Rights
2
27/03/24 67 33K
27/03/24 Last post  Piton72 Comments Created with Sketch.  67  Views Created with Sketch.  33K 
NEU
Acadia
5 6 7
26/03/24 400 169K
26/03/24 Last post  Piton72 Comments Created with Sketch.  400  Views Created with Sketch.  169K 
NEU
Neuren Media and Analyst Coverage
14 15 16
22/03/24 944 463K
22/03/24 Last post  ashgood123 Comments Created with Sketch.  944  Views Created with Sketch.  463K 
NEU
Katelin’s Turn is HERE!!!
2 3 4
16/03/24 207 104K
16/03/24 Last post  mellan Comments Created with Sketch.  207  Views Created with Sketch.  104K 

See All Discussions arrow Created with Sketch.

Timeline

Application for quotation of securities - NEU
12 Mar 14:24
 
2023 Results webinar
29 Feb 16:17
 
Neuren reports profit of $157 million for 2023
29 Feb 15:40
 
Appendix 4E and 2023 full year accounts
29 Feb 15:36
 
Neuren 2023 results investor webinar on 29 February 2024
29 Feb 09:27
 
DAYBUE net sales US$87.1 million in Q4 2023
28 Feb 09:54
 
View More arrow Created with Sketch.
(20min delay)
Last
$21.22
Change
0.450(2.17%)
Mkt cap ! $2.705B
Open High Low Value Volume
$20.76 $21.43 $20.70 $7.892M 373.7K

Buyers (Bids)

No. Vol. Price($)
1 596 $21.22
 

Sellers (Offers)

Price($) Vol. No.
$21.26 1054 1
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
$21.24
  Change
0.450 ( 2.73 %)
Open High Low Volume
$20.76 $21.42 $20.73 102057
Last updated 15.59pm 28/03/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.